NUCALA is a targeted biologic treatment indicated to treat select respiratory diseases/conditions. In May 2025, the US Food and Drug Administration approved NUCALA as add-on maintenance treatment for adult patients with poorly controlled chronic eosinophilic COPD.

To prepare for the launch of the new indication, we created a unique “Now Approved” look and feel and applied it to a suite of tactics and assets including a launch site, digital and print literature, and social media posts.